TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants Receiving a Diagnostic Audiogram
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation of curve amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major pathological response (mPR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery Asberg Depression Rating Scale (MADRS-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: days alive and free of invasive mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of misinterpretation of ILD on HRCT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of vaccinated participants developing SAEs, AEs, and AESI
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Psychological Flexibility Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recess Fidelity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in active Range of Motion of the knee joint flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in functional capacity with KOOS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived Diabetes Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diabetes Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microstructural Parameters of Ingestive Behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suck Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burst Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Selected Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRONJ healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores from the holistic complementary and alternative medicine questionnaire (HCAMQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects achieving NASH resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement of alopecia in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Macroscopic hair growth documented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microscopic hair growth evaluated by Trichoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microscopic hair growth evaluated by Trichoscan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Individual visual analog pain scores (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of moderate-to-severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first reported pain and first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV of concordant PET/MRI lesion plus PI-RADS score 4~5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPV of using negative PET lesion plus PI-RADS score 1~3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumber Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression-Free Rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Prespecified Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain assessment using the Critical-Care Pain Observation Tool (CPOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory brainstem response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Single cell RNA sequencing analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Unanticipated Serious Adverse Effect (USADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Brain activity measured by EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle activity measured by EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Motion capture data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at the end
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum volume in 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline-adjusted plasma nicotine Cmax0-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted plasma nicotine AUC0-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: New cases of anal HSIL identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of BAY 1895344
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment emergent changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment emergent changes in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Non-hematologic Adverse Events after Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of grade 3-4 cytokine release syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS)
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of knowledge about monkeypox treatment and nature of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of overall well being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of health outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St. George's Respiratory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of microscopy and/or culture-confirmed talaromycosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants attending follow-up appointments and reporting pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Weight change in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 25(OH)D Blood Serum Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of lymph node invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fMRI data on brainstem level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI data of higher cortical brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COVID-19 symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible SMM that agree to participate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of scalp surface area covered at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to event for 100% total hair coverage of the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the combined free GAGome MCED test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of delivery of Psilocybin integrated into Interpersonal Therapy
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Feasibility of recruiting patients with major depression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perioperative transfusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: resolution of fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of hypomineralized second primary molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: muscle structure variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of HFS
Endpoint domain: Adverse events/effects
Primary endpoint: Secondary Prophylaxis Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral care-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude toward oral care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy of oral care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pulmonary microvascular blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline of tidal volume loss during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of oxygen saturation levels during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of Pulmonary dynamic compliance immediately post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Clinically Significant Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI based social exclusion and social separation tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral ratings of social exclusion and social separation tasks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum observed plasma concentration (Cmax) of pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ZN-d5 Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total rescue analgesia consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration Time Curve From The Time of Dosing Extrapolated to Time Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate hemostasis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Combined Clinical Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of major congenital malformations (MCM) among live births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pediatric Anesthesia Emergence Delirium Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurovascular coupling using the dynamic retinal vessel analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects on FDA approved dose of Abemaciclib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-inf of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T½ el of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Engagement Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Nonviolent Resistance scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in emotion regulation scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neonatal composite adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Child body mass index (BMI) at 2 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Flourishing Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Treadmill Incremental Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Repeat Sprint Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline In Yoyo Intermittent Recovery Test Level 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of SynKIR310
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemically verified 7-day point prevalence abstinence from cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IJV distensibility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Results of periodontitis treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MDS-UPDRS part III during medication off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence and severity of transplant-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: adherence to phyto-aromatherapy treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of subjects after intravenous administration of 18FBB
Endpoint domain: Adverse events/effects
Primary endpoint: Ability of PET imaging to distinguish cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lateral movement of the EVAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Non-suicidal self-injury episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Contrast Sensitivity Function (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of AKIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Identification of drug-induced AKIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Change in 28-day frequency of countable seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of Individuals With Mean CGM Glucose <183 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3D RV EF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RIMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV FAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: S'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: STE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical use of rhEPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Useful Field of View (UFOV) test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Daily Everyday Cognitive Assessment (DECA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline iFunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: DN4 Neuropathic pain questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Oswestry scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean changes in postoperative optic nerve sheath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Screening to Diagnosis Ratio for Hepatitis C Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Timed 25-foot walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Functional Gait Assessment (FGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Daily stepping activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Carer reported child sleep diaries
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Resource use diaries
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Outcome of Feedback survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Index of Social Engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: absorbed doses to organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of analgesia techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between pupillometry values and numerical pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limited Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Vastus medial obliques fiber angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patella position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vulvovaginal cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical presentation of vulvovaginal cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of fatigue at diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from baseline fVAS after treatment 6 months
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of pain relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Center of Pressure (COP) control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache impact test questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Carer Preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decision-regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Digestibility and absorption of dietary protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Urine Albumin-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Units of blood obtained per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusions required around the time of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Complete ablation rate of main lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing